Venetoclax for the treatment of multiple myeloma

Iuliana Vaxman, M. Hasib Sidiqi, Morie Gertz

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Introduction: Treatment of multiple myeloma (MM) in the relapsed setting remains challenging, despite recent impressive advances in the management of these patients. Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration for treatment of chronic lymphocytic leukemia but the drug has shown activity in a number of hematological malignancies. Venetoclax has broadened the treatment options for patients with relapsed or refractory MM. Approximately, 20% of myeloma patients will exhibit t (11;14) associated with high BCL-2 expression making venetoclax an attractive therapeutic option. The efficacy of venetoclax is not uniquely restricted to this population. Areas covered: This review will summarize the mechanism of action, toxicity profile, and published data on venetoclax use in MM, moving the field toward personalized medicine in the treatment of myeloma. Expert commentary: Numerous phase 1/2 clinical trials are evaluating the efficacy and safety of venetoclax monotherapy and in combinations in the relapse setting. These trials show better outcomes in the subgroup of patients harboring t(11;14).

Original languageEnglish (US)
Pages (from-to)915-920
Number of pages6
JournalExpert Review of Hematology
Issue number12
StatePublished - Dec 2 2018


  • BCL-2
  • Multiple myeloma
  • targeted therapy
  • venetoclax

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Venetoclax for the treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this